Antiphospholipid antibodies and the antiphospholipid syndrome: Pathogenic mechanisms

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 3, 2008, Pages 236-250

  Pierangeli, Silvia S ^a   Chen, Pojen P ^b   Raschi, Elena ^c,d   Scurati, Silvia ^c,d   Grossi, Chaudia ^c,d   Borghi, Maria Orietta ^c,d   Palomo, Ivan ^e   Harris, E Nigel ^f   Meroni, Pier Luigi ^c,d  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^e UNIVERSIDAD DE TALCA   (Chile)

^f UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

Anti 2 glycoprotein I antibodies; Antiphospholipid antibodies; Decidual cells; Endothelial cell activation; Lupus anticoagulant; Platelet activation; Pregnancy loss; Thrombosis; Trophoblast

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ABCIXIMAB; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; APOLIPOPROTEIN E2; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; CYCLIC AMP; DILAZEP; FIBRINOGEN RECEPTOR; FLUINDOSTATIN; HEPARIN; LUPUS ANTICOAGULANT; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPASE A2; PHOSPHOLIPID ANTIBODY; THEOPHYLLINE; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

ANTICOAGULATION; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; CELL ACTIVATION; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; DECIDUA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENDOTHELIUM CELL; FETUS WASTAGE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; IN VITRO STUDY; IN VIVO STUDY; INTERNATIONAL NORMALIZED RATIO; LIVEDO RETICULARIS; MOLECULAR DYNAMICS; MONOCYTE; NONHUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; REPRODUCTION; REVIEW; TARGET CELL; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOSIS; TROPHOBLAST;

ABORTION, HABITUAL; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIGENS; BETA 2-GLYCOPROTEIN I; BLOOD PLATELETS; COMPLEMENT ACTIVATION; ENDOTHELIAL CELLS; FEMALE; FIBRINOLYSIS; HUMANS; INFLAMMATION MEDIATORS; MONOCYTES; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBIN; THROMBOPHILIA; THROMBOPLASTIN; TROPHOBLASTS; VENOUS THROMBOSIS;

EID: 50249189294     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0028-1082267     Document Type: Review

References (132)

1. Harris EN. Syndrome of the black swan. Br J Rheumatol 1987;26:324-326
2. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome:report of an international workshop. Arthritis Rheum 1999;42:1309-1311
3. Miyakis S, Lockshin MD, Atsumi I, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306
4. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the second international workshop for identification of lupus anticoagulants - on behalf of the Second International Workshop for identification of lupus anticoagulants and antiphospholipid antibodies of the ISTH. Thromb Haemost 1995;74:1597-1603
5. 2 glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120-4124
6. Atsumi T, Koike T. Clinical relevance of antiprothrombin antibodies. Autoimmun Rev 2002;1:49-53
7. Fleck RA, Rapaport SI, Rao LV. Antiprothrombin antibodies and the lupus anticoagulant. Blood 1988;72:512-519
8. Oosting JD, Derksen RHWM, Bobbink IWG, Hacking TM, Bouma BN, deGroot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenic mechanism? Blood 1993;83:2618-2625
9. 2glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994;83:2878-2892
10. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989;74:2426-2432
11. 2glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 2007;56:1638-1647
12. Chen XX, Gu YY, Li SJ, et al. Some plasmin-induced antibodies bind to cardiolipin, display lupus anticoagulant activity and induce fetal loss in mice. J Immunol 2007;178:5351-5356
13. Cesarman-Maus G, Rios-Luna NP, Deora AB, et al. Autoantibodies against the fibrinolytic receptor, annexin A2, in antiphospholipid syndrome. Blood 2006;107:4375-4382
14. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Mcd 1992;117:997-1002
15. Tincani A, Balestrieri G, Danieli E, et al. Pregnancy complications of the antiphospholipid syndrome. Autoimmunity 2003;36:27-32
16. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-763
17. 2glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost 2006;95:796-801
18. McClain MT, Arbuckle MR, Heinlen LD, et al. The prevalence, onset and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004;50:1226-1232
19. Ashcrson RA. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome. Immunobiology 2005;210:727-733
20. Gharavi AE, Pierangeli SS, Harris EN. Origin of antiphospholipid antibodies. Rheum Dis Clin North Am 2001;27:551-563
21. Crowther MA, GinsbergJS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133-1138
22. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005;3:848-853
23. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002;41:924-929
24. Garcia DA, Khamashta MA, Crowther MA. How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. Blood 2007;110:3122-3127
25. Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome. Arthritis Rheum 2007;56:2382-2391
26. Pierangeli SS, Colden-Stanfield M, Liu X, et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999;99:1997-2000
27. 2 glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003;101:157-162
28. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990;76:101-107
29. 2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum 1999;42:167-174
30. Escolar G, Font J, Reverter JC, et al. Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation. Arterioscler Thromb 1992;12:196-200
31. Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995;73:529-534
32. Khamashta MA, Harris EN, Gharavi AE, et al. Immune mediated mechanism for thrombosis:antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988;47:849-854
33. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994;153:1328-1332
34. Simantov R, LaSala JM, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995;96:2211-2219
35. 2 glycoprotein I and induce endothelial activation. Arthritis Rheum 1997;40:551-561
36. Cuadrado MJ, Lopez-Pedrera C, Khamashta MA, et al. Thrombosis in primary antiphospholipid syndrome - a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997;40:834-841
37. Amengual O, Atsumi T, Khamashta MA, Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998;79:276-281
38. Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005;52:1545-1554
39. Chamley LW, McKay EJ, Pattison NS. Inhibition of heparin/antithrombin III cofactor activity by anticardiolipin antibodies: a mechanism for thrombosis. Thromb Res 1993;71:103-111
40. Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002;195:211-220
41. Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005;52:2120-2124
42. Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002;87:518-522
43. Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997;96:4380-4384
44. Martinuzzo ME, Maclouf J, Carreras LO, Levy-Toledano S. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost 1993;70:667-671
45. 2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. Thromb Haemost 1998;79:42-45
46. 2 glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome. J Rheumatol 1998;25:51-56
47. 2glycoprotein I induced synthesis of human platelet thromboxane A2 in vitro. J Rheumatol 2003;30:55-59
48. Vega-Ostertag M, Harris EN, Pierangeli SS. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004;50:2911-2919
49. 2glycoprotein I for apoER2' on platelets is located in domain V. J Biol Chem 2005;280:36729-36736
50. 2glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'. J Biol Chem 2003;278:33831-33838
51. 2glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib/IX-V. Arthritis Rheum 2006;54:2558-2567
52. 2glycoprotein I inhibits von Willebrand factor-dependent platelet adhesion and aggregation. Blood 2007;110:1483-1491
53. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001;88:245-250
54. Espinola RG, Liu X, Colden-Stanfield M, Hall J, Harris EN, Pierangeli SS. E-selectin mediated pathogenic effects of antiphospholipid antibodies. J Thromb Haemost 2003;1:843-848
55. Forastiero RR, Martinuzzo M, De Larranaga G. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprous related antiphospholipid antibodies. Lupus 2005;14:129-136
56. Williams FMK, Parmar K, Hughes GRV, Hunt BJ. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost 2000;84:742-746
57. Dobado-Berrios M, Lopez-Pedrera C, Velasco F, Aguirre MA, Torres A, Cuadrado MJ. Increased levels of TF mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999;82:1578-1582
58. Martini F, Farsi A, Gori AM, et al. Antiphospholipid antibodies (aPL) increase the potential monocyte procoa-gulant activity in patients with systemic lupus erythematosus. Lupus 1996;5:206-211
59. Reverter JC, Tassies D, Font J, et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998;41:1420-1427
60. Zhou H, Wolberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004;104:2353-2358
61. Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003;48:3272-3279
62. Ferrara DE, Swerlick R, Casper K, et al. Fluvastatin inhibits upregulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004;2:1558-1563
63. Cuadrado MJ, Buendia P, Velasco F, et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost 2006;4:2461-2469
64. 2glycoprotein I antibodies. Thromb Haemost 2002;88:851-857
65. López-Pedrera C, Buendia P, Cuadrado MJ, et al. Antiphopholipid antibodies from patients with the antiphospholipid syndrome induce tissue factor expression through the simultaneous activation of NF-KappaB/Rel proteins via p38 mitogen activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006;54:301-311
66. Simoncini S, Sapet C, Camoin-Jau L, et al. Role of reactive oxygen species and p38 MAPK in the induction of the proadhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome. Int Immunol 2005;17:489-500
67. Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z, et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost 2007;5:1828-1834
68. Montiel-Manzano G, Romay-Penabad E, Papalardo de Martinez E, et al. In vivo effects of an inhibitor of nuclear factor-kappa (k) B on thrombogenic properties of anti-phospholipid antibodies. Ann N Y Acad Sci 2007;1108:540-553
69. 2glycoprotein I antibodies. J Immunol 1998;160:5572-5578
70. 2glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus 2006;15:358-365
71. 2glycoprotein I ameliorates thrombosis induced by antiphospholipid antibodies in mice [abstract]. Arthritis Rheum 2006;54(Suppl):S559
72. 2glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000;275:15541-15548
73. 2glycoprotein I antibodies. Blood 2005;105:1964-1969
74. Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003;101:3495-3500
75. Pierangeli SS, Vega-Ostertag ME, Raschi E, et al. Toll like receptor 4 is involved in antiphospholipid-mediated thrombosis: in vivo studies. Ann Rheum Dis 2007;66:1327-1333
76. 2glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007;56:2687-2697
77. Romay-Penabad Z, Liu X, Montiel-Manzano G, et al. C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. Ann N Y Acad Sci 2007;1108:554-566
78. 2glycoprotein I is complement-dependent and requires a priming factor. Blood 2005;106:2340-2346
79. Munakata Y, Saito T, Matsuda K, Seino J, Shibata S, Sasaki T. Detection of complement-fixing antiphospholipid antibodies in association with thrombosis. Thromb Haemost 2000;83:728-731
80. Carbone J, Orera M, Rodriguez-Mahou M, et al. Immunological abnormalities in primary APS evolving into SLE: 6 years follow-up in women with repeated pregnancy loss. Lupus 1999;8:274-278
81. Davis WD, Brey RL. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheumatol 1992;10:455-460
82. Zhao Y, Rumold R, Ahmed AE, et al. An IgG anti-prothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. Arthritis Rheum 1999;42:2132-2138
83. Vega-Ostertag M, Liu X, Kwna-ki H, Chen P, Pierangeli S. A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br J Haematol 2006;135:214-219
84. Hwang KK, Grossman J, Visvanathan S, et al. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin bv antithrombin. J Immunol 2001;167:7192-7198
85. Hwang KK, Yang CD, Yan W, et al. A thrombin cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum 2003;48:1622-1630
86. Yang CD, Hwang KK, Yan W, et al. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004;172:5765-5773
87. Kolev K, Gombás J, Váradi B, et al. Immunoglobulin G from patients with antiphospholipid syndrome impairs the fibrin dissolution with plasmin. Thromb Haemost 2002;87:502-508
88. Lu CS, Horizon AA, Hwang KK, et al. Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum 2005;52:4018-4027
89. Cugno M, Caribbe M, Galli M, et al. Antibodies to tissue plasmanogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in patients. Blood 2004;103:2121-2126
90. Yang YH, Hwang KK, Fitzgerald J, et al. Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin. J Immunol 2006;177:8219-8225
91. Lin WS, Chen PC, Yang CD, et al. Some antiphospholipid antibodies recognize conformational epitopes shared by (^glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 2007;56:1638-1647
92. Van Horn JT, Craven C, Ward K, Branch DW, Silver RM. Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipid-like syndromes. Placenta 2004;25:642-648
93. Nayar R, Lage JM. Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Hum Pathol 1996;27:201-206
94. Peaceman AM, Rehnberg KA. The effect of immunoglobulin G fractions from patients with lupus anticoagulant on placental prostacyclin and thromboxane production. Am J Obstet Gynecol 1993;169:1403-1406
95. Rand JH. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002;90:29-37
96. 2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007;109:1490-1494
97. Rand JH, Wu XX, Guller S, et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994;171:1566-1572
98. Out HJ, Kooijman CD, Bruinse HW, Derksen RH. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 1991;41:179-186
99. Sebire NJ, Fox H, Backos M, Rai R, Paterson C, Regan L. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod 2002;17:1067-1071
100. Lyden TW, Vogt E, Ng AK, Johnson PM, Rote NS. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J Reprod Immunol 1992;22:1-14
101. Sthoeger ZM, Mozes E, Tartakovsky B. Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc Natl Acad Sci U S A 1993;90:6464-6467
102. 2glycoprotein I. Arthritis Rheum 2000;43:140-150
103. Ornoy A, Yacobi S, Matalon S, et al. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture. Lupus 2003;12:573-578
104. 2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet 1998;352:1037-1038
105. Vogt E, Ng AK, Rote NS. A model for the antiphospholipid antibody syndrome: monoclonal antiphosphatidylserine antibody induces intrauterine growth restriction in mice. Am J Obstet Gynecol 1996;174:700-707
106. Katsuragawa H, Kanzaki H, Inoue T, Hirano T, Mori T, Rote NS. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion. Biol Reprod 1997;56:50-58
107. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A 1991;88:3069-3073
108. Ikematsu W, Luan FL, La Rosa L, et al. Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice. Arthritis Rheum 1998;41:1026-1039
109. Aplin JD, Haigh T, Lacey H, Chen CP, Jones CJ. Tissue interactions in the control of trophoblast invasion. J Reprod Fertil Suppl 2000;55:57-64
110. Castellucci M, De Matteis R, Meisser A, et al. Leptin modulates extracellular matrix molecules and metallo-proteinases: possible implications for trophoblast invasion. Mol Hum Reprod 2000;6:951-958
111. Di Simone N, Castellani R, Calandro D, Caruso A. Antiphospholid antibodies regulate the expression of trophoblast cell adhesion molecules. Fertil Steril 2002;77:805-811
112. Francis J, Rai R, Sebire NJ, et al. Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. Mol Hum Reprod 2006;12:435-442
113. 2glyco-protein I antibodies [abstract]. Clin Exp Rheumatol 2007;2:35
114. Bose P, Black S, Kadyrov M, et al. Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol 2004;191:2125-2131
115. Matalon ST, Shoenfeld Y, Blank M, Yacobi S, von Landenberg P, Ornoy A. Antiphosphatidylserine antibodies affect rat yolk sacs in culture: a mechanism for fetal loss in antiphospholipid syndrome. Am J Reprod Immunol 2004;51:144-151
116. 2glycoprotein I antibodies affect Bcl-2 and Bax trophoblast expression without evidence of apoptosis. Ann N Y Acad Sci 2006;1069:364-376
117. Chaouat G. The Th1/Th2 paradigm: still important in pregnancy? Semin Immunopathol 2007;29:95-113
118. Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003;112:1644-1654
119. Berman J, Girardi G, Salmon JE. TNF-α is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005;174:485-490
120. Girardi G, Redecha P, Salmon J. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004;10:1222-1226
121. Piona A, La Rosa L, Tincani A, et al. Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti-cardiolipin antibodies in pregnant naive BALB/c mice. Scand J Immunol 1995;41:427-432
122. Martinez de la Torre Y, Buracchi C, Borroni EM, et al. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci U S A 2007;104:2319-2324
123. Redecha P, Tilley R, Tentati M, et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007;110:2423-2431
124. Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007;196:167el-5
125. Cavazzana I, Nebuloni M, Cetin I, et al. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? J Autoimmun 2007;28:160-164
126. McIntyre JA. Immune recognition at the maternal-fetal interface: overview. Am J Reprod Immunol 1992;28:127-131
127. 2glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome. J Rheumatol 1994;21:1684-1693
128. 2glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994;152:653-659
129. 2glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J Immunol 1996;157:3744-3751
130. 2gh/coprotein I antibodies in vitro. Ann Rheum Dis 2005;64:462-467
131. Meroni P, Raschi E, Ronda N, Borghi MO. Humoral autoimmunity against endothelium: theory or reality? Trends Immunol 2005;26:275-281
132. 2glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the antiphospholipid syndrome. J Biol Chem 2002;277:2644-2649